Brian Cheng
Stock Analyst at JP Morgan
(2.20)
# 2,819
Out of 5,113 analysts
71
Total ratings
43.1%
Success rate
-1.59%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $70 → $125 | $69.93 | +78.75% | 1 | Dec 10, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.32 | - | 1 | Nov 20, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $68 → $81 | $83.10 | -2.53% | 6 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Underweight | $12 → $5 | $14.63 | -65.82% | 5 | Nov 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $20 → $18 | $12.78 | +40.85% | 5 | Nov 6, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $71 → $82 | $117.63 | -30.29% | 1 | Nov 6, 2025 | |
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $23.24 | -1.03% | 3 | Oct 16, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Underweight | n/a | $1.72 | - | 5 | Oct 10, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Underweight | n/a | $1.30 | - | 1 | Oct 10, 2025 | |
| ABSI Absci | Initiates: Overweight | n/a | $2.91 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $33 | $26.01 | +26.87% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $47 | $53.81 | -12.66% | 2 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $22.58 | -11.43% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $55.52 | +26.08% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.76 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $25.87 | -14.96% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $26.48 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.16 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $9.76 | +238.11% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.69 | +255.03% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.35 | +3,863.76% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.61 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $320 → $96 | $8.44 | +1,037.44% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.08 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.70 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $7.53 | +1,028.82% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $6.79 | +209.28% | 1 | Aug 3, 2021 |
Kymera Therapeutics
Dec 10, 2025
Maintains: Overweight
Price Target: $70 → $125
Current: $69.93
Upside: +78.75%
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.32
Upside: -
Protagonist Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $68 → $81
Current: $83.10
Upside: -2.53%
Intellia Therapeutics
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $14.63
Upside: -65.82%
Xencor
Nov 6, 2025
Maintains: Overweight
Price Target: $20 → $18
Current: $12.78
Upside: +40.85%
Revolution Medicines
Nov 6, 2025
Maintains: Overweight
Price Target: $71 → $82
Current: $117.63
Upside: -30.29%
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $23.24
Upside: -1.03%
Allogene Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.72
Upside: -
Pliant Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.30
Upside: -
Absci
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $2.91
Upside: -
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $26.01
Upside: +26.87%
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $53.81
Upside: -12.66%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $22.58
Upside: -11.43%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $55.52
Upside: +26.08%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $4.76
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $25.87
Upside: -14.96%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $26.48
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.16
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $9.76
Upside: +238.11%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.69
Upside: +255.03%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.35
Upside: +3,863.76%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.61
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $320 → $96
Current: $8.44
Upside: +1,037.44%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.08
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $2.70
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $7.53
Upside: +1,028.82%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $6.79
Upside: +209.28%